Trials / Completed
CompletedNCT03160482
PACE4 in Thyroid Cancer
Evaluation of PACE4 Isoforms as Biomarkers in Thyroid Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 39 (actual)
- Sponsor
- Robert Day · Academic / Other
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
The investigation of thyroid nodules is limited by the fact that up to 49% of the fine needle aspirations (FNA) performed are of "indeterminate cytological signification". Moreover, no fully reliable molecular marker for thyroid cancer have been described. The goal of this project is to study the expression of a specific kind of protein convertase in benign and in malignant thyroid nodules to determine its potential as a biomarker.
Detailed description
Patients that underwent thyroidectomy at the CIUSSS de l'Estrie-CHUS will be recruited and classified according to the pathological diagnosis. An immunohistochemistry technique, developed and calibrated for the specific protein convertase studied, will be undertaken. Results will be interpreted by a specialized pathologist.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Immunohistochemistry | Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue. |
Timeline
- Start date
- 2017-05-15
- Primary completion
- 2018-01-15
- Completion
- 2018-01-15
- First posted
- 2017-05-19
- Last updated
- 2018-10-02
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03160482. Inclusion in this directory is not an endorsement.